Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477666 | 0.85 | RAB9A (0.55) | RAB9AROCK2ALDH1A1TYK2 | |
| SCHEMBL20916924 | 0.85 | RAB9A (0.55) | RAB9AROCK2ALDH1A1TYK2 | |
| SCHEMBL5529298 | 0.82 | RAB9A (0.68) | RAB9AROCK2TDP1MAPK8ALDH1A1 | |
| SCHEMBL5523941 | 0.82 | MAPK8 (0.57) | RAB9AROCK2TDP1MAPK8 | |
| SCHEMBL30693359 | 0.82 | MAPK8 (0.57) | RAB9AROCK2TDP1MAPK8 | |
| SCHEMBL1326862 | 0.80 | RAB9A (0.57) | RAB9AROCK2TDP1ALDH1A1 | |
| SCHEMBL5518570 | 0.79 | RAB9A (0.56) | RAB9AROCK2TDP1ALDH1A1P2RY1 | |
| SCHEMBL14892703 | 0.79 | KCNK3 (0.44) | MAPK8MAPK10 | |
| SCHEMBL1307403 | 0.79 | CYP1A2 (0.42) | ALDH1A1P2RY1P2RY14P2RY2 | |
| SCHEMBL351860 | 0.77 | CTNNB1 (0.55) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | RAB9A 902/4885ROCK2 1013/4885TDP1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.